摘要
目的了解诺和锐30联合二甲双胍治疗对口服降糖药控制不理想的2型糖尿病患者血糖控制的有效性和安全性。方法通过对26例口服降糖药治疗血糖和糖化血红蛋白控制不佳的2型糖尿病患者，用诺和锐30联合二甲双胍治疗12周的观察。在治疗前和第12周分别测空腹血糖，早餐后2h血糖，以及糖化血红蛋白水平，并观察治疗前和治疗后12周的低血糖发生情况。结果患者使用诺和锐30联合二甲双胍治疗12周后，FPG、PPG值明显低于治疗前，HbA1C的达标率明显高于治疗前，两组数据相比差异有统计学意义。结论诺和锐30联合二甲双胍治疗对口服降糖药控制不佳的2型糖尿病患者可以进一步降低血糖和糖化血红蛋白．低血糖发生率低。诺和锐30联合二甲双胍治疗是口服降糖药控制不佳的2型糖尿病患者安全有效的治疗方案。
Objective To investigate the efficacy and satefy of biphasic insulin aspart 30 （ BIAsp 30 ） in combination with metformin to treat diabetic patients whose glucose are poorly controlled with oral antidiabetic drugs（OADs）. Methods 26 type 2 diabetes whose glucose and HbAlc were not controlled well with oral antidiabetic drugs ,they were then treated with biphasic insulin aspart 30 and metformin for 12 weeks. Fasting blood glucose（ FBG）, postprandial 2 -hour blood glucose（PBG） and HbAlc were measured at 0 week and 12 week respectively. Hypoglycemia was also observed. Results The levels of FPG, PPG and HbAI c were significantly lower at 12 week compared with 0 week （ P 〈 0. 05 ）. Conclusion BIAsp 30 in combination with metformin offered greater reduction in FPG, PPG and HbA1 c without increasing risk of hypoglycemia. The combination of BIAsp 30 and metformin is a good and safe choice in subjects with type 2 diabetes inadequately controlled with oral antidiabetic drugs.
出处
《中外医学研究》
2009年第13期28-29,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
